SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE (UP TO 3 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES

被引：0
|
作者：
Deodhar, A. [1 ]
Baraliakos, X. [2 ]
Marzo-Ortega, H. [3 ,4 ]
Sieper, J. [5 ]
Gupta, A. D. [6 ]
Porter, B. [7 ]
Fox, T. [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Ruhr Univ Bochum, Bochum, Germany
[3] Univ Leeds, Leeds Teaching Hosp Trust, Leeds, W Yorkshire, England
[4] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[5] Charite, Berlin, Germany
[6] Novartis Healthcare, Hyderabad, India
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Novartis Pharma AG, Basel, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
174
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [31] Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
    Schett, Georg
    Baraliakos, Xenofon
    Van den Bosch, Filip
    Deodhar, Atul
    Ostergaard, Mikkel
    Das Gupta, Ayan
    Mpofu, Shephard
    Fox, Todd
    Winseck, Adam
    Porter, Brian
    Shete, Abhijit
    Gensler, Lianne S.
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (08) : 1251 - 1258
  • [32] Reduction in fatigue in patients with active psoriatic arthritis is sustained over 2 years: long-term results of two phase 3 studies of secukinumab
    Kvien, T. K.
    Gossec, L.
    Conaghan, P.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 33 - 33
  • [33] REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS ARE SUSTAINED OVER 2 YEARS: LONG-TERM RESULTS OF TWO PHASE 3 STUDIES WITH SECUKINUMAB
    Gossec, L.
    Kvien, T. K.
    Conaghan, P. G.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 351 - 351
  • [34] SECUKINUMAB DEMONSTRATES RAPID AND SUSTAINED EFFICACY IN ANKYLOSING SPONDYLITIS PATIENTS WITH NORMAL OR ELEVATED BASELINE C-REACTIVE PROTEIN LEVELS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES
    Barkham, Nick
    Braun, Juergen
    Sieper, Joachim
    Landewe, Robert
    Baraliakos, Xenofon
    Miceli-Richard, Corinne
    Quebe-Fehling, Erhard
    Porter, Brian
    Gandhi, Kunal
    van der Heijde, Desiree
    RHEUMATOLOGY, 2019, 58 : 153 - 154
  • [35] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN ANKYLOSING SPONDYLITIS PATIENTS: A POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 TRIALS
    Deodhar, Atul
    Schett, Georg
    Baraliakos, Xenofon
    Van den Bosch, Filip
    Gensler, Lianne
    Ostergaard, Mikkel
    Agawane, Shital
    Gupta, Ayan
    Mpofu, Shephard
    Fox, Todd
    Winseck, Adam
    Porter, Brian
    Shete, Abhijit
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 7 - 7
  • [36] Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies
    Blauvelt, A.
    Paul, C.
    van de Kerkhof, P.
    Warren, R. B.
    Gottlieb, A. B.
    Langley, R. G.
    Brock, F.
    Arendt, C.
    Boehnlein, M.
    Lebwohl, M.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (04) : 640 - 651
  • [37] Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
    Karel Pavelka
    Alan Kivitz
    Eva Dokoupilova
    Ricardo Blanco
    Marco Maradiaga
    Hasan Tahir
    Luminita Pricop
    Mats Andersson
    Aimee Readie
    Brian Porter
    Arthritis Research & Therapy, 19
  • [38] Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
    Pavelka, Karel
    Kivitz, Alan
    Dokoupilova, Eva
    Blanco, Ricardo
    Maradiaga, Marco
    Tahir, Hasan
    Pricop, Luminita
    Andersson, Mats
    Readie, Aimee
    Porter, Brian
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [39] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES
    Kvien, T. K.
    Deodhar, A.
    Gossec, L.
    Conaghan, P. G.
    Strand, V.
    Ostergaard, M.
    Williams, N.
    Porter, B.
    Gandhi, K.
    Jugl, S.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S9 - S9
  • [40] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES
    Kvien, T. K.
    Deodhar, A.
    Gossec, L.
    Conaghan, P. G.
    Strand, V.
    Ostergaard, M.
    Williams, N.
    Porter, B.
    Gandhi, K.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 355 - 356
12345